Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 2

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
This study was aimed at the comparison of the pharmacokinetics of 4 different parenteral commercial specialties containing enrofloxacin as an active substance. For this purpose, 35 2-3-years-old, male mix-breed dogs were used. Five groups including 7 animals each were established. Each animal included in the first group (group 1) was intravenously administered a reference standard for enrofloxacin at a dose of 5 mg/kg body weight. Groups 2, 3, 4 and 5 were administered different parenteral preparations containing enrofloxacin at the same dose but intramuscularly. Subsequent to drug administration, blood samples were collected from all of the groups at 0.083, 0.25, 0.50, 1, 2, 4, 6, 12, 24, and 36 hours. The blood samples were centrifuged for the separation of sera. Enrofloxacin analyses in serum samples were performed by means of the spectrofluorometric method. Upon evaluation based on pharmacokinetic distribution and according to the findings obtained, a statistically significant difference was determined in other groups with respect to A₁, α, t1/2α, V₁ ve k₁₀ when compared to administration by route IV. This difference was demonstrated to be in the form of a decrease for A₁*, α and k₁₀, and increase for t1/2α and V₁, when compared to administration by route IV. Excluding t1/2α, statistically significant differences were not observed between all the commercial preparations (groups 2-5).
Twenty-eight mix-breed male dogs of approximately 3 years of age and with similar body weights were used in the study. Four groups, each including 7 animals, were established. The animals included in the first, second, third, and fourth groups were administered formulations A, B, C, and D, respectively, containing 200 mg sulfadoxine and 40 mg trimethoprim per millilitre, at a dose of 25 mg/kg body weight sulfadoxine by intramuscular route at the same site of the body. Subsequently, blood samples were collected at 0.083, 0.25, 0.50, 1.0, 1.5, 2.0, 4.0, 6.0, 12 and 24 hours. The levels of sulfadoxine-trimethoprim in the plasma samples were measured by means of a HPLC device. Pharmacokinetic calculations were performed in compliance with the two-compartment open model. According to statistical analyses, amongst the parameters evaluated, significant differences were determined to exist between the groups only with respect to the mathematical coefficients (A₂*), hybrid rate constant for terminal elimination phase (β), half life at α phase (t½α), half life at β phase (t½β) and mean residence time (MRT) values for sulfadoxine, and with respect to the A₁*, first order absorption rate constant (kₐ), β and MRT values for trimethoprim (p < 0.05).
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.